Supplementary Material: Prednisone dosage is the primary modifiable risk factor for infection in pemphigus with rituximab treatment: A retrospective analysis of 105 patients

Supplementary material for "Infection Risk in Rituximab-Treated Pemphigus Vulgaris" (Saksena et al., JAAD) Contains five supplementary tables and one supplementary figure: infection outcomes by treatment group and prednisone dose (Table I); patient demographics and treatment characteristics (Table II); patient comorbidities (Table III); infection episodes by severity and pathogen type (Table IV); additional multivariable models for predictors of infection (Table V); and a Kaplan-Meier analysis of infection-free survival across treatment regimens (Figure I).